top of page

Scientific publications

ARTICLES

​​

  1. Hamilton EP, Loibl S, Bachelot T, Gnant M, Niikura N, Park YH, Tolaney SM, Pistilli B, Rastogi P, Saini KS, Gioni I, Johnston S, Nunes R, Quintana A, Stuart M, Syta E, Walding A, Klinowska T, Mayer IA. CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer. Future Oncol. 2025 Mar;21(7):795-806. doi: 10.1080/14796694.2025.2459548. Epub 2025 Feb 27. PMID: 40017004; PMCID: PMC11916374.

  2. Quintana A, Kamal S. Saini, Laura Vidal, Vicente Peg, Felipe Slebe, Sibylle Loibl, Giuseppe Curigliano, Peter Schmid, Javier Cortes. Window of opportunity trials with immune checkpoint inhibitors in triple negative breast cancer. ESMO Open 2024. Volume 9, Issue 10, 103713

  3. Saini KS, Somara S, Ko HC, Thatai P, Quintana A, Wallen ZD, Green MF, Mehrotra R, McGuigan S, Pang L, Das S, Yadav K, Neric D, Cantini L, Joshi C, Iwamoto K, Dubbewar S, Vidal L, Chico I, Severson E, Lorini L, Badve S, Bossi P. Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy. Front Oncol. 2024 Oct 8;14:1473706.

  4. Pinal-Fernandez I*, Quintana A*, Milisenda JC*, Casal-Dominguez M*, Muñoz-Braceras S, Derfoul A, Torres-Ruiz J, Pak K, Dell'Orso S, Naz F, Gutierrez-Cruz G, Milone M, Shelly S, Duque-Jaimez Y, Tobias-Baraja E, Matas-Garcia A, Garrabou G, Padrosa J, Ros J, Trallero-Araguás E, Walitt B, Christopher-Stine L, Lloyd TE, Zhao C, Swift S, Rajan A, Grau-Junyent JM, Selva-O'Callaghan A, Liewluck T, Mammen AL. Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Ann Rheum Dis. 2023 Jun;82(6):829-836. (*co-first authors).

  5. Li M, Quintana A, Alberts E, Hung MS, Boulat V, Ripoll MM, Grigoriadis A. B Cells in Breast Cancer Pathology. Cancers (Basel). 2023 Feb 28;15(5):1517.

  6. Czajka-Francuz P, Prendes MJ, Mankan A, Quintana Á, Pabla S, Ramkissoon S, Jensen TJ, Peiró S, Severson EA, Achyut BR, Vidal L, Poelman M, Saini KS. Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy. Front Oncol. 2023 Jun 22;13:1200646.

  7. Salifu I, Singh N, Berraondo M, Remon J, Salifu S, Severson E, Quintana A, Peiró S, Ramkissoon S, Vidal L, Chico I, Saini KS. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer. Cancer Treat Res Commun. 2023; 36:100713. doi: 10.1016/j.ctarc.2023.100713.

  8. Quintana Á, Arenas EJ, Bernadó C, Navarro JF, González J, Esteve-Codina A, Moliné T, Marti M, Curigliano G, Schmid P, Peg V, Arribas J, Cortés J. Evaluation of triple negative breast cancer with heterogeneous immune infiltration. Front Immunol. 2023 May 4;14:1149747.

  9. Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R, Schmid P, Curigliano G, Muñoz-Couselo E, Perez-García J, Marti M, Blanco-Heredia J, Anjos CD, Vazquez M, De Mattos-Arruda L, Cortés J. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. Eur J Cancer. 2021 May;148:134-145.

  10. El Bairi K et al. International Immuno-Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 1;7(1):150.

  11. Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O'Callaghan A, Pardos-Gea J, Quintana A, Mekinian A, Anunciacion-Llunell A, Miró-Mur F. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020 Jul;19(7):102569.

​

POSTERS

​

  1. S Loibl, Y Park, S Tolaney, I Gioni, S Johnston, T Klinowska, I A Mayer, R Nunes, B Pistilli, M Stuart, A Quintana, A Walding, M Gnant; Abstract PO4-27-07: A Phase 3, randomized, open-label study of upfront camizestrant vs standard endocrine therapy as adjuvant treatment for ER-positive/HER2-negative early breast cancer with intermediate-high or high risk of recurrence (CAMBRIA-2). Cancer Res 1 May 2024; 84 (9_Supplement): PO4–27–07.

  2. A. Quintana, V. Peg, T. Moline, A. Prat, L. Paré, P. Galván, G. Villacampa, R. Dientsmann, J. Perez, E. Muñoz, M. Martí, J. Blanco-Heredia, C. Dos Anjos, M. Vazquez, L. de Mattos, J. Cortés. Immune Analysis of Lymph Nodes in Relation to the Presence or Absence of Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancers. ESMO BREAST 2020 Annals of Oncology (2020) 31 (suppl_2): S15-S41.

  3. Morales-Barrera R, González M, Suarez C, Ros J, Fernandez C, Serra E, Mateo J, Lozano F, Martin-Liberal J, Quintana A, Dienstmann R, Serrano C, Garralda E, Carles J. Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors. Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

  4. Morales-Barrera R, Suarez C, González M, Ros J, Serra E, Semidey M, Mateo J, Fernandez C, Lozano F, Mast R, Roche S, Quintana A, Serrano C, Valverde C, de Torres I, Maldonado X, Morote J, Carles J. Impact of immune-related adverse events on survival in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors. Journal of Clinical Oncology (2019) 37, no. 15_suppl 4531-4531

bottom of page